PE20020616A1 - Compuestos de piperidina como antagonistas del receptor ccr-3 - Google Patents
Compuestos de piperidina como antagonistas del receptor ccr-3Info
- Publication number
- PE20020616A1 PE20020616A1 PE2001000683A PE2001000683A PE20020616A1 PE 20020616 A1 PE20020616 A1 PE 20020616A1 PE 2001000683 A PE2001000683 A PE 2001000683A PE 2001000683 A PE2001000683 A PE 2001000683A PE 20020616 A1 PE20020616 A1 PE 20020616A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ccr
- phenyl
- halogen
- receptor
- Prior art date
Links
- 102000004499 CCR3 Receptors Human genes 0.000 title abstract 2
- 108010017316 CCR3 Receptors Proteins 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- -1 CARBOXYL Chemical class 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical group OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DE PIPERIDINA DE FORMULA I DONDE: Ar1 ES FENILO SUSTITUIDO POR HALOGENO; Ar2 ES FENILO, NAFTILO OPCIONALMENTE SUSTITUIDO POR HALOGENO, CIANO, HIDROXILO, NITRO, ALQUILO C1-C8, HALOALQUILO C1-C8, ALCOXILO C1-C8, ALCOXICARBONILO C1-C8; R1 ES H, ALQUILO C1-C8 OPCIONALMENTE SUSTITUIDO POR OH, ALCOXILO C1-C8, ACILOXILO, NR2R3, HALOGENO, CARBOXILO, ALCOXI-CARBONILO C1-C8, CONR4R5; R2 Y R3 SON H, ALQUILO C1-C8; R2 ES H; R3 ES ACILO, SO2R6; R2 Y R3 JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R4 Y R5 SON H, ALQUILO C1-C8 O JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R6 ES ALQUILO C1-C8, HALOALQUILO C1-C8, FENILO; n ES 1-4; CUANDO Ar1 ES p-CLOROFENILO; R1 ES H; Ar2 NO ES FENILO O p-NITROFENILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I SE PUEDE UTILIZAR JUNTO CON ANTIINFLAMATORIO, BRONCODILATADOR, ANTIHISTAMINA Y ES ANTAGONISTA DEL RECEPTOR CCR-3 E INHIBE LA INFILTRACION Y ACTIVACION DE CELULAS INFLAMATORIAS (EOSINOFILOS) E INHIBE LA RESPUESTA ALERGICA CCR-3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0017174A GB0017174D0 (en) | 2000-07-12 | 2000-07-12 | Organic compounds |
| GB0023326A GB0023326D0 (en) | 2000-09-22 | 2000-09-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020616A1 true PE20020616A1 (es) | 2002-08-02 |
Family
ID=26244644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000683A PE20020616A1 (es) | 2000-07-12 | 2001-07-10 | Compuestos de piperidina como antagonistas del receptor ccr-3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6670379B2 (es) |
| EP (1) | EP1303488B1 (es) |
| JP (1) | JP2004502756A (es) |
| KR (1) | KR20030036603A (es) |
| CN (1) | CN1184204C (es) |
| AR (1) | AR031597A1 (es) |
| AT (1) | ATE447553T1 (es) |
| AU (2) | AU8197201A (es) |
| BR (1) | BR0112456A (es) |
| CA (1) | CA2412941C (es) |
| CZ (1) | CZ200375A3 (es) |
| DE (1) | DE60140366D1 (es) |
| ES (1) | ES2334886T3 (es) |
| HU (1) | HUP0301341A2 (es) |
| IL (1) | IL153661A0 (es) |
| MX (1) | MXPA02012848A (es) |
| MY (1) | MY126139A (es) |
| NO (1) | NO324760B1 (es) |
| NZ (1) | NZ523414A (es) |
| PE (1) | PE20020616A1 (es) |
| PL (1) | PL358673A1 (es) |
| PT (1) | PT1303488E (es) |
| SK (1) | SK272003A3 (es) |
| TW (1) | TWI227231B (es) |
| WO (1) | WO2002004420A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ES2348290T3 (es) * | 2000-10-09 | 2010-12-02 | Novartis Ag | Amidas n-(4-ariloxipiperidin-1-ilalquil) cinámicas como antagonistas del receptor de ccr3-3. |
| GB0114699D0 (en) * | 2001-06-15 | 2001-08-08 | Novartis Ag | Organic compounds |
| WO2005025578A1 (en) * | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JP6473133B2 (ja) * | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1003514A4 (en) * | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| JP3475177B2 (ja) | 1998-11-17 | 2003-12-08 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アロイルピペリジンｃｃｒ−３受容体拮抗剤ｉｉｉ |
| EP1140087A4 (en) * | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| PL350904A1 (en) * | 1999-03-26 | 2003-02-10 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-07-09 TW TW090116691A patent/TWI227231B/zh not_active IP Right Cessation
- 2001-07-10 CZ CZ200375A patent/CZ200375A3/cs unknown
- 2001-07-10 US US10/332,642 patent/US6670379B2/en not_active Expired - Fee Related
- 2001-07-10 JP JP2002509087A patent/JP2004502756A/ja active Pending
- 2001-07-10 AR ARP010103261A patent/AR031597A1/es unknown
- 2001-07-10 HU HU0301341A patent/HUP0301341A2/hu unknown
- 2001-07-10 KR KR10-2003-7000445A patent/KR20030036603A/ko not_active Withdrawn
- 2001-07-10 IL IL15366101A patent/IL153661A0/xx unknown
- 2001-07-10 MX MXPA02012848A patent/MXPA02012848A/es active IP Right Grant
- 2001-07-10 CA CA2412941A patent/CA2412941C/en not_active Expired - Fee Related
- 2001-07-10 BR BR0112456-0A patent/BR0112456A/pt not_active IP Right Cessation
- 2001-07-10 EP EP01960488A patent/EP1303488B1/en not_active Expired - Lifetime
- 2001-07-10 CN CNB018126111A patent/CN1184204C/zh not_active Expired - Fee Related
- 2001-07-10 AT AT01960488T patent/ATE447553T1/de not_active IP Right Cessation
- 2001-07-10 ES ES01960488T patent/ES2334886T3/es not_active Expired - Lifetime
- 2001-07-10 PE PE2001000683A patent/PE20020616A1/es not_active Application Discontinuation
- 2001-07-10 NZ NZ523414A patent/NZ523414A/en unknown
- 2001-07-10 SK SK27-2003A patent/SK272003A3/sk not_active Application Discontinuation
- 2001-07-10 MY MYPI20013274A patent/MY126139A/en unknown
- 2001-07-10 WO PCT/EP2001/007941 patent/WO2002004420A1/en not_active Ceased
- 2001-07-10 DE DE60140366T patent/DE60140366D1/de not_active Expired - Lifetime
- 2001-07-10 PT PT01960488T patent/PT1303488E/pt unknown
- 2001-07-10 AU AU8197201A patent/AU8197201A/xx active Pending
- 2001-07-10 PL PL01358673A patent/PL358673A1/xx not_active Application Discontinuation
- 2001-07-10 AU AU2001281972A patent/AU2001281972B2/en not_active Ceased
-
2003
- 2003-01-10 NO NO20030135A patent/NO324760B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2412941C (en) | 2011-01-04 |
| HUP0301341A2 (hu) | 2003-08-28 |
| ES2334886T3 (es) | 2010-03-17 |
| IL153661A0 (en) | 2003-07-06 |
| AR031597A1 (es) | 2003-09-24 |
| BR0112456A (pt) | 2003-07-22 |
| EP1303488A1 (en) | 2003-04-23 |
| US6670379B2 (en) | 2003-12-30 |
| WO2002004420A1 (en) | 2002-01-17 |
| AU2001281972B2 (en) | 2004-06-03 |
| PT1303488E (pt) | 2010-01-19 |
| MXPA02012848A (es) | 2003-05-15 |
| MY126139A (en) | 2006-09-29 |
| DE60140366D1 (de) | 2009-12-17 |
| NZ523414A (en) | 2004-07-30 |
| NO324760B1 (no) | 2007-12-10 |
| CN1441780A (zh) | 2003-09-10 |
| JP2004502756A (ja) | 2004-01-29 |
| SK272003A3 (en) | 2003-07-01 |
| TWI227231B (en) | 2005-02-01 |
| CA2412941A1 (en) | 2002-01-17 |
| NO20030135L (no) | 2003-02-19 |
| EP1303488B1 (en) | 2009-11-04 |
| NO20030135D0 (no) | 2003-01-10 |
| PL358673A1 (en) | 2004-08-09 |
| US20030176460A1 (en) | 2003-09-18 |
| CZ200375A3 (cs) | 2003-04-16 |
| ATE447553T1 (de) | 2009-11-15 |
| AU8197201A (en) | 2002-01-21 |
| CN1184204C (zh) | 2005-01-12 |
| KR20030036603A (ko) | 2003-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020616A1 (es) | Compuestos de piperidina como antagonistas del receptor ccr-3 | |
| PE20020580A1 (es) | Aminotiazoles como antagonistas del receptor de adenosina | |
| PE20020485A1 (es) | Derivados de quinolina y quinazolina como antagonistas del neuropeptido y | |
| CY1108573T1 (el) | Ανταγωνιστες νρυυ5 | |
| ECSP066329A (es) | Derivados de pentanol heterocíclicamente sustituidos, procedimiento para su preparación y su uso como anti-inflamatorios | |
| PE20020508A1 (es) | DERIVADOS DE PIRIDINA COMO INHIBIDORES DE LA ACTIVIDAD DE LA QUINASA IkB ß | |
| PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
| NO20061978L (no) | Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon | |
| PE20061093A1 (es) | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| HUP0201659A2 (hu) | Kristályos benzimidazol-vegyület | |
| PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
| NO20022318D0 (no) | Nye forbindelser | |
| AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
| ES8700252A1 (es) | Procedimiento para preparar nuevos compuestos indolicos | |
| PE20050951A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| ATE340795T1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
| PE20000728A1 (es) | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda | |
| EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
| ATE260275T1 (de) | Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one | |
| AR053790A1 (es) | Acidos biariloximetilarencarboxilicos. procesos de obtencion y composiciones farmaceuticas. | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
| ATE365730T1 (de) | Neuartige verbindungen | |
| SE7713846L (sv) | Benzimidazoler och forfarande for deras framstellning | |
| PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |